-
Product Insights
NewNet Present Value Model: Kezar Life Sciences Inc’s Zetomipzomib Maleate
Empower your strategies with our Net Present Value Model: Kezar Life Sciences Inc's Zetomipzomib Maleate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Famitinib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Famitinib in Triple-Negative Breast Cancer (TNBC) Drug Details: Famitinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zetomipzomib Maleate in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zetomipzomib Maleate in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zetomipzomib Maleate in Systemic Lupus Erythematosus Drug Details: Zetomipzomib maleate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zetomipzomib Maleate in Autoimmune Hepatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zetomipzomib Maleate in Autoimmune Hepatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zetomipzomib Maleate in Autoimmune Hepatitis Drug Details: Zetomipzomib maleate is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zetomipzomib Maleate in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zetomipzomib Maleate in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zetomipzomib Maleate in Lupus Nephritis Drug Details: Zetomipzomib maleate is under development...
-
Product Insights
NewDermatomyositis – Drugs In Development, 2024
Empower your strategies with our Dermatomyositis – Drugs In Development, 2024 report and make more profitable business decisions. Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids. The Dermatomyositis drugs in development market research report provide comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage...
-
Product Insights
NewOcular Melanoma – Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
NewLupus Nephritis – Drugs In Development, 2024
Empower your strategies with our Lupus Nephritis – Drugs In Development, 2024 report and make more profitable business decisions. Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function. In systSLE, the body's immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with...
-
Product Insights
NewPolymyositis – Drugs In Development, 2024
Empower your strategies with our Polymyositis – Drugs In Development, 2024 report and make more profitable business decisions. Polymyositis are a group of rare diseases called the inflammatory myopathies that involve chronic (long-standing) muscle inflammation and weakness, and in some cases, pain. Myopathy is used to describe a number of conditions affecting the muscles. All myopathies can cause muscle weakness. Both children and adults can be affected. The Polymyositis drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewUveal Melanoma – Drugs In Development, 2024
Empower your strategies with our Uveal Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common...